SK pharmteco Announces Appointment of a New President for SK biotek Ireland

Press Release | For Immediate Release 
SK pharmteco Inc (SKPT) is pleased to announce that Joyce Fitzharris, currently serving as General Manager, SK biotek Ireland has been promoted to the office of President, SK biotek Ireland. Growth in our business base and projected expansions continue to support SK biotek Ireland’s position as a key contributor to SKPT’s EU and worldwide business.

“Joyce has been leading our Irish Operation, based in Swords, Dublin, since December 2019. Under her leadership, SK biotek Ireland has grown financially. She has transformed both the business and organization. Joyce has been at the forefront of implementing strategies with the pursuit of qualitative growth, operational excellence, acceleration of cost reduction and productivity improvement. SK biotek Ireland is strengthening its competitiveness as a CDMO and playing a key role in the global network of SK pharmteco.” said Dr. Aslam Malik, CEO of SK pharmteco, the parent company of SK biotek Ireland.

“I am delighted to be a part of the growing SK pharmteco Global CDMO organization and know the Swords Campus will continue to contribute and play a key part in that growth.” “Our business in Ireland is growing and we continue to expand our capabilities in what we offer to Customers. The Irish Team is excited to play our part in the manufacture of critical APIs for our Customers and their patients worldwide” shares Ms. Fitzharris.

Joyce has worked within the Active Pharmaceutical Ingredients (API) business for 30 years. She has held multiple Technical, Compliance, Operational Excellence and Leadership positions with increasing levels of responsibility with Bristol Myers Squibb and SK biotek Ireland.

Joyce holds a B.Sc. Analytical Science from Dublin City University, a M.Sc. Environmental Protection from Sligo IT and a M.Sc. Emergency Management from Dublin City University.

— Ends —

SK pharmteco is the single customer-facing team comprised of SK biotek Ireland, AMPAC Fine Chemicals, SK biotek Korea and Yposkesi. Creating substantial market synergies in the API CDMO space by combining highly complementary assets and expertise, this union enables us to provide the highest-quality services to our customers.

With world-class state-of-the-art facilities and technology, increased capabilities: energetic chemistry, continuous flow process, controlled substances, particle engineering, high potency – with world-class potent handling capability (down to low nanogram per cubic meter levels). We have multiple cGMP manufacturing and development sites, with ~960m³ of capacity among 6 sites plus a dedicated analytical services facility across USA, Korea and Ireland.

SK pharmteco is a portfolio company of SK Inc. (South Korea) and serves as a strategic part of SK’s growing pharmaceutical sector.

SK biotek Ireland, our facility in Dublin, known as Swords Campus has been manufacturing API and Intermediates for almost 60 years. For the last 30+ years, Swords Campus has maintained its leadership in the development, scale-up and commercial manufacture of highly potent chemical intermediates and API. SK biotek Ireland can today offer multi-scale plants (from grams to 100s of kg) capable of handling material with Occupational Exposure Limit (OEL) ≤ 10 ng/m³.

This integrated facility combines manufacturing plants, R&D and QC laboratories within the same building. Through the implementation of strong safety compliance policy and adherence to high-quality and safety standards, Swords Campus has a proven track record as a reliable supplier of HPAPIs to multiple customers.

Additional information about SK biotek can be obtained by visiting our website at

For clarification or further information contact:
Patrick Park, VP, Head of Global Business Development, SK pharmteco
Telephone: +1 (916) 357-6376 or email

Photos attached include: Joyce Fitzharris, SK biotek Ireland x 2

Scroll to Top

Enter your details to access Marketing Materials